Studies have demonstrated that the proteosome inhibitor bortezomib exerted a promising antitumor effect in human MTC cells through the inhibition of IκB degradation, which led to the inactivation of the transcriptional factor NF-κB [106]. This evidence concerns the gene NFKB1 and medullary thyroid gland carcinoma.